Elevated levels of 1-hydroxypyrene and N′-nitrosonornicotine in smokers with head and neck cancer: A matched control study

Head and Neck

Volumn 35, Issue 8, 2013, Pages 1096-1100

  Khariwala, Samir S ^a,b   Carmella, Steven G ^b   Stepanov, Irina ^b   Fernandes, Patricia ^a   Lassig, Amy Anne ^a   Yueh, Bevan ^a,b   Hatsukami, Dorothy ^b   Hecht, Stephen S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

biomarkers; carcinogenesis; head and neck cancer; metabolites; tobacco

Indexed keywords

1 HYDROXYPYRENE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; CREATININE; NITROSONORNICOTINE;

ALCOHOL CONSUMPTION; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SMOKING; TOBACCO; URINALYSIS;

BIOMARKERS; CARCINOGENESIS; HEAD AND NECK CANCER; METABOLITES; TOBACCO;

ADULT; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CREATININE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NITROSAMINES; PYRENES; PYRIDINES; SMOKING;

EID: 84870417920     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23085     Document Type: Article

References (31)

1. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R,. Mortality from smoking worldwide. Br Med Bull 1996; 52: 12-21.
2. World Health Organization. Tobacco or health: a global status report. Geneva: World Health Organization; 1997.
3. Schlecht NF, Franco EL, Pintos J, Kowalski LP,. Effect of smoking cessation and tobacco type on the risk of cancers in the upper aerodigestive tract in Brazil. Epidemiology 1999; 10: 412-418.
4. Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 1994; 86: 131-137.
5. Sturgis EM, Wei Q, Spitz MR,. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 2004; 31: 726-733.
6. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ,. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
7. Centers for Disease Control and Prevention (CDC). Tobacco use among adults-United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55: 1145-1148.
8. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults and trends in smoking cessation-United States, 2008. MMWR Morb Mortal Wkly Rep 2009; 58: 1227-1232.
9. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S,. Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010; 2010: 701657.
10. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004; 83: 1-1438.
11. Hecht SS,. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998; 11: 559-603.
12. Yuan JM, Koh WP, Murphy SE, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res 2009; 69: 2990-2995.
13. Carmella SG, Le Ka KA, Upadhyaya P, Hecht SS,. Analysis of N- and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Chem Res Toxicol 2002; 15: 545-550.
14. Carmella SG, Han S, Fristad A, Yang Y, Hecht SS,. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Cancer Epidemiol Biomarkers Prev 2003; 12 (11 Pt 1): 1257-1261.
15. Hecht SS,. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002; 23: 907-922.
16. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. IARC Monogr Eval Carcinog Risks Hum 2010; 92: 1-853.
17. Carmella SG, Chen M, Han S, et al. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol 2009; 22: 734-741.
18. Hecht SS, Yuan JM, Hatsukami D,. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol 2010; 23: 1001-1008.
19. Stepanov I, Hecht SS,. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiol Biomarkers Prev 2005; 14: 885-891.
20. Du X, Squier CA, Kremer MJ, Wertz PW,. Penetration of N-nitrosonornicotine (NNN) across oral mucosa in the presence of ethanol and nicotine. J Oral Pathol Med 2000; 29: 80-85.
21. Carmella SG, Akerkar SA, Richie JP Jr, Hecht SS,. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiol Biomarkers Prev 1995; 4: 635-642.
22. Carmella SG, Le KA, Hecht SS,. Improved method for determination of 1-hydroxypyrene in human urine. Cancer Epidemiol Biomarkers Prev 2004; 13: 1261-1264.
23. Hochalter JB, Zhong Y, Han S, Carmella SG, Hecht SS,. Quantitation of a minor enantiomer of phenanthrene tetraol in human urine: correlations with levels of overall phenanthrene tetraol, benzo[a]pyrene tetraol, and 1-hydroxypyrene. Chem Res Toxicol 2011; 24: 262-268.
24. Stepanov I, Carmella SG, Briggs A, et al. Presence of the carcinogen N′-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res 2009; 69: 8236-8240.
25. Porubin D, Hecht SS, Li ZZ, Gonta M, Stepanov I,. Endogenous formation of N′-nitrosonornicotine in F344 rats in the presence of some antioxidants and grape seed extract. J Agric Food Chem 2007; 55: 7199-7204.
26. Stepanov I, Hecht SS,. Detection and quantitation of N′- nitrosonornicotine in human toenails by liquid chromatography-electrospray ionization-tandem mass spectrometry. Cancer Epidemiol Biomarkers Prev 2008; 17: 945-948.
27. Alexandrie AK, Warholm M, Carstensen U, et al. CYP1A1 and GSTM1 polymorphisms affect urinary 1-hydroxypyrene levels after PAH exposure. Carcinogenesis 2000; 21: 669-676.
28. Hecht SS,. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 733-744.
29. Hoffmann D, Hecht SS,. In:, Cooper CS, Grover PL, editors. Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag; 1990. pp. 63-102.
30. Yuan JM, Knezevich AD, Wang R, Gao YT, Hecht SS, Stepanov I,. Urinary levels of the tobacco-specific carcinogen N′-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis 2011; 32: 1366-1371.
31. Church TR, Anderson KE, Caporaso NE, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev 2009; 18: 260-266.